IMUNON CEO Issues Letter to Shareholders
Reviews 2022 accomplishments; sets forth 2023 milestones and long-term vision LAWRENCEVILLE, N.J., March 01, 2023…
ISP
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Inspirato Incorporated (ISPO) on Behalf of Investors
LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm,…
BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data
ANAHEIM, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – BioCorRx Inc. (OTCQB: BICX)…
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress
Initiated the global Phase 2 study of NTLA-2002, a CRISPR-based, potential single-dose treatment for hereditary…
First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level
Trem-cel exhibited robust engraftment five months post-transplant through three cycles of Mylotarg Mylotarg treatment enriched…
First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level
Trem-cel exhibited robust engraftment five months post-transplant through three cycles of Mylotarg Mylotarg treatment enriched…
Telesis Bio Releases BioXp® Select mRNA Synthesis Kit to Expand the Utility, Speed, and Impact of Its Automated Synthetic Biology Workstation
Scientists Can Now Begin the mRNA Synthesis Process from Their Own Sequence or Plasmid DNA…
TransCode Therapeutics Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an…
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company Updates
CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage…
Bitdefender Enhances Premium VPN Service with App Traffic Optimizer Feature
New Feature Allows Users to Prioritize Bandwidth for Any Application on the Fly Ensuring Blazing…
Viridian Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
WALTHAM, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company…
Ubiquiti Inc. Reports Second Quarter Fiscal 2023 Financial Results
~ Revenues of $493.6 million ~ ~ GAAP Diluted Earnings Per Share of $1.86 ~…
Sorrento Issues “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock
SAN DIEGO, Jan. 29, 2023 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted…
Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued an “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock
PALO ALTO, Calif., Jan. 29, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX) announced…
iSpecimen Appoints Eric Langlois as Chief Revenue Officer
Mr. Langlois Led iSpecimen to 3,000 Percent Revenue Growth During His Tenure as the Company’s…
iSpecimen to Participate in the Sequire Biotechnology Conference on February 2, 2023
LEXINGTON, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the…
iSpecimen to Participate in Maxim’s Healthcare IT Virtual Conference on January 25, 2023
LEXINGTON, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the…
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
Shoreline to obtain an exclusive license to SLEEK knock-in technology for iPSC-derived NK cells, an…
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
Pivotal Phase III IMbrave050 study investigating Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma…
Reverence Capital Partners Selects CAIS for Efficient Access to the Independent Wealth Channel
Alts Demand Continues to Rise Amid Challenging Market NEW YORK–(BUSINESS WIRE)–CAIS, the leading alternative investment…